PulseAGGREGATOR

Home Feed Stories Sources Features

PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Your news command center for 10,000+ sources. Search, filter, and set alerts — then cut through the noise with bias analysis, story clustering, and blindspot detection.

Endpoints News

healthCenter

1d ago

GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfronttranslating…

GSK will spend $110 million upfront for a license to a KRAS-EGFR antibody conjugate developed by Hutchmed, with up to $1.185 billion in biobucks on the line.

 The Chinese biopharma said ...

Factuality

76/100

Political Bias

Center

Ownership

Endpoints News

Country

USA

Region

North America

Language

English

Keywords#GSK#KRAS-EGFR#Hutchmed’s#Hutchmed’s KRAS-EGFR#hutchmed

Read Original ↗ Article view

Comments

Loading comments…

GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront | Pulse Aggregator